Current Cardiology Reports

, 15:410 | Cite as

Antiarrhythmic Drugs 2013: State of the Art

Invasive Electrophysiology and Pacing (J Singh, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Invasive Electrophysiology and Pacing


Antiarrhythmic drugs are widely used, but are of modest efficacy and have important side effects. However, even with the advance of catheter ablation for atrial fibrillation and ventricular tachycardia, antiarrhythmic drugs remain an important tool for treating arrhythmias. Antiarrhythmic drug development has remained slow despite much effort given our limited understanding of what role various ionic currents play in arrhythmogenesis and how they are modified by arrhythmias. This review will focus on promising new antiarrhythmic drugs undergoing clinical investigation or currently approved for clinical use, including amiodarone analogues, agents with novel ionic targets, and new drug combinations.


Atrial fibrillation Ventricular tachycardia Antiarrhythmic drugs Amiodarone analogues Dronedarone Celivarone Budiodarone Ranolazine Vernakalant Azimilide Ivabradine Drug synergy 


Compliance with Ethics Guidelines

Conflict of Interest

Kapil Kumar and Peter J. Zimetbaum declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    • LafAuente-Lafuente C, Longas-Tejero MA, Bergmann JF, et al. Cochrane review 2012 antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2012;5:CD005049. Excellent review of current clinically available antiarrhythmic drugs and their limitations.Google Scholar
  2. 2.
    The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33.Google Scholar
  3. 3.
    Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–40.PubMedCrossRefGoogle Scholar
  4. 4.
    Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667–77.PubMedCrossRefGoogle Scholar
  5. 5.
    Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987–99.PubMedCrossRefGoogle Scholar
  6. 6.
    Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety ofdronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597–605.PubMedCrossRefGoogle Scholar
  7. 7.
    Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668–78.PubMedCrossRefGoogle Scholar
  8. 8.
    Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678–87.PubMedCrossRefGoogle Scholar
  9. 9.
    Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365(24):2268–76.PubMedCrossRefGoogle Scholar
  10. 10.
    Morey TE, Seubert CN, Raatkainen MJP, et al. Structure-activity relationships and electrophysiological effects of short-acting amiodarone homologs in guinea pig isolated heart. J Pharmacol Exp Ther. 2000;297:260–6.Google Scholar
  11. 11.
    Arya A, Silberbauer J, Teichman SL, et al. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace. 2009;11:458–64.PubMedCrossRefGoogle Scholar
  12. 12.
    Ezekowitz MD, Nagarakanti R, Lubinski A, et al. A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2012;34:1–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Gautier P, Guillemare E, Djandjighian L, et al. In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects. J Cardiovasc Pharmacol. 2004;44:244–57.PubMedCrossRefGoogle Scholar
  14. 14.
    Gojkovic O, Aliot EM, Capucci A, et al. Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverterdefibrillator interventions. Hear Rhythm. 2012;9:217–24.CrossRefGoogle Scholar
  15. 15.
    Kowey PR, Crijns HJGM, Aliot EM, et al. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE Study. Circulation. 2011;124:2649–60.PubMedCrossRefGoogle Scholar
  16. 16.
    Khitri AR, Aliot EM, Capucci A, et al. Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter. J Cardiovasc Electrophysiol. 2012;23:462–47.PubMedCrossRefGoogle Scholar
  17. 17.
    Wettwer E, Hala O, Christ T, et al. Role of IKur in controlling action potential shape and contractility in the human atrium. Influence of chronic atrial fibrillation. Circulation. 2004;110:2299–306.PubMedCrossRefGoogle Scholar
  18. 18.
    Voigt N et al. Left to right atrial inward-rectifier potassium current gradients in patient was paroxysmal versus chronic atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:472–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Burashnikov A, Pourrier M, Gibson JK, et al. Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol. Circ Arrhythm Electrophysiol. 2012;5(2):400–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Naccarelli GV, Wolbrette DL, Samii S, et al. Vernakalant: pharmacology electrophysiology, safety and efficacy. Drugs Today (Barc). 2008;44:325–9.CrossRefGoogle Scholar
  21. 21.
    Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117:1518–25.PubMedCrossRefGoogle Scholar
  22. 22.
    Roy D, Pratt C, Juul-Moller S, et al. Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: results of a phase III, randomized, placebo-controlled, multicenter trial [abstract]. J Am Coll Cardiol. 2006;47:10A.Google Scholar
  23. 23.
    Kowey PR, Roy D, Pratt CM, et al. Efficacy and safety of vernakalant hydrochloride injection for the treatment of atrial fibrillation after valvular or coronary artery bypass surgery. Circulation. 2007:114.Google Scholar
  24. 24.
    Wettwer E, Christ T, Endig S, et al. The new antiarrhythmic drug Vernakalant: ex-vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation. Cardiovasc Res. 2013;98(1):145–54.PubMedCrossRefGoogle Scholar
  25. 25.
    Lynch Jr JJ, Regan CP, Beatch GN, et al. Comparison of the intrinsic vasorelaxant and inotropic effects of the antiarrhythmic agents vernakalant and flecainide in human isolated vascular and cardiac tissues. J Cardiovasc Pharmacol. 2013;61(3):226–32.PubMedCrossRefGoogle Scholar
  26. 26.
    Cheng JWM, Rybak I. Pharmacotherapy options in atrial fibrillation: focus on vernakalant. Clin Med Therapeutics. 2009;1:215–30.Google Scholar
  27. 27.
    Torp-Pedersen C, Raev DH, Dickinson G, et al. A randomized, placebo-controlled study of vernakalant (Oral) for the prevention of atrial fibrillation recurrence after cardioversion. Circ Arrhythm Electrophysiol. 2011;4:637–43.PubMedCrossRefGoogle Scholar
  28. 28.
    Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775–83.PubMedCrossRefGoogle Scholar
  29. 29.
    Bunch TJ, Mahapatra S, Murdock DK, et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin Electrophysiol. 2011;34:1600–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Murdock DK, Kaliebe JW, Overton N. Ranolazine-induced suppression of ventricular tachycardia in a patient with non-ischemic cardiomyopathy: a case report. Pacing Clin Electrophysiol. 2008;31:765–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Kaliebe JW, Murdock DK. Suppression of non-sustained ventricular tachycardia with ranolazine: a case report. WMJ. 2009;108:373–5.PubMedGoogle Scholar
  32. 32.
    Nanda S, Levin V, Martinez MW, et al. Ranolazine—treatment of ventricular tachycardia and symptomatic ventricular premature beats in ischemic cardiomyopathy. Pacing Clin Electrophysiol. 2010;33:e119–120.PubMedCrossRefGoogle Scholar
  33. 33.
    Murdock DK, Kaliebe JW. Suppression of frequent ventricular ectopy in a patient with hypertrophic heart disease with ranolazine: a case report. Indian Pacing Electrophysiol J. 2011;11:84–8.PubMedGoogle Scholar
  34. 34.
    Tagarakis GI, Aidonidis I, Daskalopoulou SS, et al. Effect of Ranolazine in Preventing Postoperative Atrial Fibrillation in Patients Undergoing Coronary Revascularization Surgery. Curr Vasc Pharmacol. 2012 Nov 7. [Epub ahead of print].Google Scholar
  35. 35.
    Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2011;108:673–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Murdock DK, Kersten M, Kaliebe J, et al. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J. 2009;9:260–7.PubMedGoogle Scholar
  37. 37.
    Murdock DK, Kaliebe J, Larrain G. The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series. Pacing Clin Electrophysiol. 2012;35:302–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Murdock DK, Overton N, Kersten M, et al. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J. 2008;8:175–81.PubMedGoogle Scholar
  39. 39.
    Burashnikov A, Antzelevitch C. Role of late sodium channel current block in the management of atrial fibrillation. Cardiovasc Drugs Ther. 2013;27:79–89.PubMedCrossRefGoogle Scholar
  40. 40.
    Fredj S, Sampson KJ, Liu H, et al. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol. 2006;148:16–24.PubMedCrossRefGoogle Scholar
  41. 41.
    Beyder A, Strege PR, Reyes S, et al. Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel NaV1.5: a novel mechanism of drug action. Circulation. 2012;125:2698–706.PubMedCrossRefGoogle Scholar
  42. 42.
    Parikh A, Mantravadi R, Kozhevnikov D, et al. Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2. Hear Rhythm. 2012;9:953–60.CrossRefGoogle Scholar
  43. 43.
    Page RL, Connolly SJ, Wilkinson WE, et al. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response. Am Heart J. 2002;143:643–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Page RL, Tilsch TW, Connolly SJ, et al. Asymptomatic or “silent” atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation. 2003;107:1141–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Lombardi F, Borggrefe M, Ruzyllo W, et al. Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-cardiOversion MaintEnance Trial-II) trial. Eur Heart J. 2006;27:2224–31.PubMedCrossRefGoogle Scholar
  46. 46.
    Kerr CR, Connolly SJ, Kowey P, et al. Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. Am J Cardiol. 2006;98:215–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Dorian P, Borggrefe M, Al-Khalidi HR, et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation. 2004;110:3646–54.PubMedCrossRefGoogle Scholar
  48. 48.
    Conway E, Musco S, Kowey PR. New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? Am J Cardiol. 2008;102(suppl):12H–9H.PubMedCrossRefGoogle Scholar
  49. 49.
    Dorian P, Al-Khalidi HR, Hohnloser SH, et al. Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial. J Am Coll Cardiol. 2008;52:1076–83.PubMedCrossRefGoogle Scholar
  50. 50.
    Savelieva I, Camm AJ. If inhibition with ivabradine: electrophysiologic effects and safety. Drug Saf. 2008;31:95–107.PubMedCrossRefGoogle Scholar
  51. 51.
    Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet. 2008;372:807–16.PubMedCrossRefGoogle Scholar
  52. 52.
    Borer JS, Bohm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT study. Eur Heart J. 2012;33:2813–20.PubMedCrossRefGoogle Scholar
  53. 53.
    Cappato R, Castelvecchio S, Ricci C, et al. Clinical efficacy of ivavradine in patients with inappropriate sinus tachycardia. J Am Coll Cardiol. 2012;60:1323–9.PubMedCrossRefGoogle Scholar
  54. 54.
    McDonald C, Frith J, Newton. Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace. 2011;13:427–30.PubMedCrossRefGoogle Scholar
  55. 55.
    Sutton R, Salukhe T. Ivabradine in the treatment of orthostatic intolerance. Europace. 2011;13:306–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Bohora S, Lokhandwala Y, Parekh P, et al. Reveral fo tachycardiomyopathy due to left atrial tachycardia by ivabradine. J Cardiovasc Electrophysiol. 2011;22:340–2.PubMedCrossRefGoogle Scholar
  57. 57.
    • Burashnikov A, Sicouri S, Di Diego JM, et al. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol. 2010;56:1216–24. First study to demonstrate synergistic effects between ranolazine and dronedarone in vitro.PubMedCrossRefGoogle Scholar
  58. 58.
    Verrier RL, Pagotto VPF, Kanas AF, et al. Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia. Hear Rhythm. 2013;10:121–7.CrossRefGoogle Scholar
  59. 59.
    Fragakis N, Koskinas KC, Katritsis DG, et al. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. Am J Cardiol. 2012;110:673–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Harvard Vanguard Medical AssociatesBostonUSA
  2. 2.Division of CardiologyBeth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations